Design of non-covalent dual-acting inhibitors for proteases MPRO and PLPRO of coronavirus SARS-CoV-2 through evolutionary library generation, pharmacophore profile matching, and molecular docking calculations

Authors

DOI:

https://doi.org/10.15587/2519-4852.2024.313808

Keywords:

SARS-CoV-2, Mpro protease, PLpro protease, dual inhibitors, virtual pharmacophore screening, docking

Abstract

The proteases of the SARS-CoV-2 coronavirus are crucial for the virus's life cycle, making them a prime target for developing antiviral drugs to combat COVID-19. Currently, there is a priority to develop new antiviral drugs that can target multiple viral proteins at once. In this study, we analyze the molecular mechanisms of how non-covalent inhibitors interact with the main protease (Mpro) and papain-like (PLpro) protease of SARS-CoV-2 to create a computer modelling algorithm for discovering ligands that can inhibit both Mpro and PLpro simultaneously.

Aim of the study. We aim to analyze the molecular structures involved in the interactions between current non-covalent inhibitors and the Mpro and PLpro proteases of SARS-CoV-2. The goal is to identify a common molecular structure that could be used to discover new inhibitors with a dual-acting mode using computer simulations.

Materials and Methods. LigandScout 4.5 software was used for 3D-pharmacophore analysis, virtual screening and molecular docking. AutoDock Vina 1.1.2 tools was utilized for molecular docking. Web-servers PLIP (Protein-Ligand Interaction Profiler) and Pharmit were used for studying molecular binding mechanisms. Generation of evolutionary libraries was performed by DataWarrior 6.0. Analysis and visualization were performed by Discovery Studio 2024 Suite.

Results. Our study analyzed various models of SARS-CoV-2 protease binding sites available in the Protein Data Bank (PDB) and their corresponding non-covalent inhibitor ligands. This analysis helped identify important features of the Mpro and PLpro ligands. By comparing the pharmacophore models of Mpro ligands with the structural features of PLpro inhibitors, we identified ligands that could potentially match the binding sites of both proteases. Using the structures of these ligands, an evolutionary library was created in the DataWarrior program. Virtual screening of this library using both Mpro and PLpro pharmacophores revealed several new hit molecules. Molecular docking of these molecules into the active sites of the Mpro and PLpro proteases and calculating their binding energetics led to the identification of several molecules and their corresponding scaffolds with dual inhibition potential. These findings can be further studied in vitro with the aim of discovering drugs for COVID-19.

Conclusions. We used computer-based screening to search for ligands that could bind to both Mpro and PLpro proteases. After identifying these potential compounds, we developed synthesis methods to obtain them for further in vitro biological activity studies

Supporting Agency

  • Grant No. 87/0062 (2021.01/0062) “Molecular design, synthesis and screening of new potential antiviral pharmaceutical ingredients for the treatment of infectious diseases COVID-19” from the National Research Foundation of Ukraine

Author Biographies

Larysa Yevsieieva, V. N. Karazin Kharkiv National University

Senior Lecturer

School of Chemistry

Pavlo Trostianko, V. N. Karazin Kharkiv National University

PhD Student

School of Chemistry

Alexander Kyrychenko, V. N. Karazin Kharkiv National University

Doctor of Chemical Sciences, Senior Researcher

School of Chemistry

Volodymyr Ivanov, V. N. Karazin Kharkiv National University

Doctor of Chemical Sciences, Professor

School of Chemistry

Sergiy Kovalenko, V. N. Karazin Kharkiv National University

Doctor of Chemical Sciences, Professor

School of Chemistry

Oleg Kalugin, V. N. Karazin Kharkiv National University

PhD, Professor

School of Chemistry

References

  1. Yevsieieva, L. V., Lohachova, K. O., Kyrychenko, A., Kovalenko, S. M., Ivanov, V. V., Kalugin, O. N. (2023). Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2. RSC Advances, 13 (50), 35500–35524. https://doi.org/10.1039/d3ra06479d
  2. Abel, R., Paredes Ramos, M., Chen, Q., Pérez-Sánchez, H., Coluzzi, F., Rocco, M. et al. (2020). Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. Frontiers in Chemistry, 8. https://doi.org/10.3389/fchem.2020.590263
  3. Zagórska, A., Czopek, A., Fryc, M., Jończyk, J. (2024). Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents. Biomolecules, 14 (7), 797. https://doi.org/10.3390/biom14070797
  4. Han, H., Gracia, A. V., Røise, J. J., Boike, L., Leon, K., Schulze-Gahmen, U. et al. (2023). A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication. RSC Advances, 13 (16), 10636–10641. https://doi.org/10.1039/d3ra00426k
  5. Prajapati, J., Patel, R., Rao, P., Saraf, M., Rawal, R., Goswami, D. (2022). Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study. Structural Chemistry, 33 (5), 1619–1643. https://doi.org/10.1007/s11224-022-01932-0
  6. Diogo, M. A., Cabral, A. G. T., de Oliveira, R. B. (2024). Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors. Pathogens, 13 (10), 825. https://doi.org/10.3390/pathogens13100825
  7. Shi, Y., Dong, L., Ju, Z., Li, Q., Cui, Y., Liu, Y. et al. (2023). Exploring potential SARS-CoV-2 Mpro non-covalent inhibitors through docking, pharmacophore profile matching, molecular dynamic simulation, and MM-GBSA. Journal of Molecular Modeling, 29 (5). https://doi.org/10.1007/s00894-023-05534-3
  8. Unoh, Y., Uehara, S., Nakahara, K., Nobori, H., Yamatsu, Y., Yamamoto, S. et al. (2022). Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. Journal of Medicinal Chemistry, 65 (9), 6499–6512. https://doi.org/10.1021/acs.jmedchem.2c00117
  9. Shionogi Announces Xocova® (Ensitrelvir Fumaric Acid) Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection (2024). Shionogi. Available at: https://www.shionogi.com/global/en/news/2024/03/20240305.html
  10. Qomara, W. F., Primanissa, D. N., Amalia, S. H., Purwadi, F. V., Zakiyah, N. (2021). Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. International Journal of General Medicine, 14, 8557–8571. https://doi.org/10.2147/ijgm.s332458
  11. Huynh, T., Cornell, W., Luan, B. (2021). In silico Exploration of Inhibitors for SARS-CoV-2’s Papain-Like Protease. Frontiers in Chemistry, 8. https://doi.org/10.3389/fchem.2020.624163
  12. Sivakumar, D., Stein, M. (2021). Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases. Biomolecules, 11 (6), 802. https://doi.org/10.3390/biom11060802
  13. Di Sarno, V., Lauro, G., Musella, S., Ciaglia, T., Vestuto, V., Sala, M. et al. (2021). Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization. European Journal of Medicinal Chemistry, 226, 113863. https://doi.org/10.1016/j.ejmech.2021.113863
  14. Tumskiy, R. S., Tumskaia, A. V., Klochkova, I. N., Richardson, R. J. (2023). SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. Computers in Biology and Medicine, 153, 106449. https://doi.org/10.1016/j.compbiomed.2022.106449
  15. Kattula, B., Reddi, B., Jangam, A., Naik, L., Adimoolam, B. M., Vavilapalli, S. et al. (2023). Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 MPro and PLPro. International Journal of Biological Macromolecules, 242, 124772. https://doi.org/10.1016/j.ijbiomac.2023.124772
  16. Kyrychenko, A., Bylov, I., Geleverya, A., Kovalenko, S., Zhuravel, I., Fetyukhin, V., Langer, T. (2024). Computer-aided rational design and synthesis of new potential antihypertensive agents among 1,2,3-triazole-containing nifedipine analogs. ScienceRise: Pharmaceutical Science, 3 (49), 4–12. https://doi.org/10.15587/2519-4852.2024.291626
  17. Lohachova, K. O., Sviatenko, A. S., Kyrychenko, A., Ivanov, V. V., Langer, T., Kovalenko, S. M., Kalugin, O. N. (2024). Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2. Journal of Applied Pharmaceutical Science, 14 (5), 232–239. https://doi.org/10.7324/japs.2024.158114
  18. Shen, J.-X., Du, W.-W., Xia, Y.-L., Zhang, Z.-B., Yu, Z.-F., Fu, Y.-X., Liu, S.-Q. (2023). Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study. International Journal of Molecular Sciences, 24 (4), 4237. https://doi.org/10.3390/ijms24044237
  19. Wolber, G., Langer, T. (2004). LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters. Journal of Chemical Information and Modeling, 45 (1), 160–169. https://doi.org/10.1021/ci049885e
  20. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4–17. https://doi.org/10.1016/j.addr.2012.09.019
  21. Sander, T., Freyss, J., von Korff, M., Rufener, C. (2015). DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis. Journal of Chemical Information and Modeling, 55 (2), 460–473. https://doi.org/10.1021/ci500588j
  22. RCSB Protein Data Bank. Available at: https://www.rcsb.org
  23. Goodsell, D. S., Morris, G. M., Olson, A. J. (1996). Automated docking of flexible ligands: Applications of autodock. Journal of Molecular Recognition, 9(1), 1–5. https://doi.org/10.1002/(sici)1099-1352(199601)9:1<1::aid-jmr241>3.0.co;2-6
  24. Trott, O., Olson, A. J. (2009). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31 (2), 455–461. https://doi.org/10.1002/jcc.21334
  25. Protein-Ligand Interaction Profiler. Available at: https://plip-tool.biotec.tu-dresden.de/plip-web/plip/index
  26. Pharmit. Available at: https://pharmit.csb.pitt.edu
  27. Adasme, M. F., Linnemann, K. L., Bolz, S. N., Kaiser, F., Salentin, S., Haupt, V. J., Schroeder, M. (2021). PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Research, 49 (W1), W530–W534. https://doi.org/10.1093/nar/gkab294
  28. Sunseri, J., Koes, D. R. (2016). Pharmit: interactive exploration of chemical space. Nucleic Acids Research, 44 (W1), W442–W448. https://doi.org/10.1093/nar/gkw287
  29. Anokhin, D., Kovalenko, S., Trostianko, P., Kyrychenko, A., Zakharov, A., Zubatiuk, T. et al. (2024). Towards the discovery of molecules with anti-COVID-19 activity: Relationships between screening and docking results. Kharkiv University Bulletin. Chemical Series, 42, 6–14. https://doi.org/10.26565/2220-637X-2024-42-01
  30. Silin, O. V., Savchenko, T. I., Kovalenko, S. M., Nikitchenko, V. M., Ivachtchenko, A. V. (2004). Synthesis of Novel 5H-Pyrazolo[4,3-c]quinolines. Heterocycles, 63 (8), 1883–1890. https://doi.org/10.3987/com-04-10092
  31. Savchenko, T. I., Silin, O. V., Kovalenko, S. M., Musatov, V. I., Nikitchenko, V. M., Ivachtchenko, A. V. (2007). Alkylation of 3‐Phenyl‐1H‐pyrazolo[4,3‐c] quinoline: Theoretical Analysis of Regioselectivity. Synthetic Communications, 37 (8), 1321–1330. https://doi.org/10.1080/00397910701227077
  32. Xiao, Y.-Q., Long, J., Zhang, S.-S., Zhu, Y.-Y., Gu, S.-X. (2024). Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review. Bioorganic Chemistry, 147, 107380. https://doi.org/10.1016/j.bioorg.2024.107380
  33. Yang, Y., Luo, Y.-D., Zhang, C.-B., Xiang, Y., Bai, X.-Y., Zhang, D., Fu, Z.-Y. et al. (2024). Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro). ACS Omega, 9 (32), 34196–34219. https://doi.org/10.1021/acsomega.4c03023
  34. Tyndall, J. D. A. (2022). S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2. Journal of Medicinal Chemistry, 65 (9), 6496–6498. https://doi.org/10.1021/acs.jmedchem.2c00624
  35. Kawajiri, T., Kijima, A., Iimuro, A., Ohashi, E., Yamakawa, K., Agura, K. et al. (2023). Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir. ACS Central Science, 9 (4), 836–843. https://doi.org/10.1021/acscentsci.2c01203
  36. Song, L., Gao, S., Ye, B., Yang, M., Cheng, Y., Kang, D. et al. (2024). Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors. Acta Pharmaceutica Sinica B, 14 (1), 87–109. https://doi.org/10.1016/j.apsb.2023.08.004
  37. Taylor, A. J., Amporndanai, K., Rietz, T. A., Zhao, B., Thiruvaipati, A., Wei, Q. et al. (2024). Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PLpro). ACS Medicinal Chemistry Letters, 15 (8), 1351–1357. https://doi.org/10.1021/acsmedchemlett.4c00238
  38. Magwaza, N. N., Mushebenge, A. G.-A., Ugbaja, S. C., Mbatha, N. A., Khan, R. B., Kumalo, H. M. (2024). Mechanistic Insights into Targeting SARS-CoV-2 Papain-like Protease in the Evolution and Management of COVID-19. BioChem, 4 (3), 268–299. https://doi.org/10.3390/biochem4030014
  39. Schimunek, J., Seidl, P., Elez, K., Hempel, T., Le, T., Noé, F. et al. (2023). A community effort in SARS‐CoV‐2 drug discovery. Molecular Informatics, 43 (1). https://doi.org/10.1002/minf.202300262
  40. Ivanov, V., Lohachova, K., Kolesnik, Y., Zakharov, A., Yevsieieva, L., Kyrychenko, A. et al. (2023). Recent advances in computational drug discovery for therapy against coronavirus SARS-CoV-2. ScienceRise: Pharmaceutical Science, 6 (46), 4–24. https://doi.org/10.15587/2519-4852.2023.290318
  41. Puhl, A. C., Godoy, A. S., Noske, G. D., Nakamura, A. M., Gawriljuk, V. O., Fernandes, R. S. et al. (2023). Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2. ACS Omega, 8 (25), 22603–22612. https://doi.org/10.1021/acsomega.3c01110
Design of non-covalent dual-acting inhibitors for proteases MPRO and PLPRO of coronavirus SARS-CoV-2 through evolutionary library generation, pharmacophore profile matching, and molecular docking calculations

Downloads

Published

2024-11-19

How to Cite

Yevsieieva, L., Trostianko, P., Kyrychenko, A., Ivanov, V., Kovalenko, S., & Kalugin, O. (2024). Design of non-covalent dual-acting inhibitors for proteases MPRO and PLPRO of coronavirus SARS-CoV-2 through evolutionary library generation, pharmacophore profile matching, and molecular docking calculations. ScienceRise: Pharmaceutical Science, (6(52), 15–26. https://doi.org/10.15587/2519-4852.2024.313808

Issue

No. 6(52) (2024)

Section

Pharmaceutical Science

License

Copyright (c) 2024 Larysa Yevsieieva, Pavlo Trostianko, Alexander Kyrychenko, Volodymyr Ivanov, Sergiy Kovalenko, Oleg Kalugin

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.